Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Autor: Buske, C, Kwak, LW, Jurczak, W, Sancho, JM, Zhavrid, E, Kim, JS, Hernandez-Rivas, JA, Prokharau, A, Vasilica, M, Nagarkar, R, Tumyan, G, Kim, WS, Ogura, M, Lee, SJ, Kim, SH, Ahn, KY

Publikováno v: Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::8b73eaa102929c16220ac05e7f4fec00
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3023

Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study.

Autor: Kwak LW; Comprehensive Cancer Center, Duarte, CA 91010., Sancho JM; Hematology Department, The Catalan Institute of Oncology-The Josep Carreras Leukemia Research Institute, Hospital Germans Trias i Pujol, Carretera Canyet, Badalona, 08916, Spain., Cho SG; Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, 06591, South Korea., Nakazawa H; Department of Hematology, Shinshu University School of Medicine, Nagano 390-8621, Japan., Suzumiya J; Shimane University Hospital, Innovative Cancer Center/Oncology-Hematology, Izumo, Shimane 693-8501, Japan., Tumyan G; Division of Hematology and Bone Marrow Transplantation, N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Science, Moscow, 115478, Russia., Kim JS; Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, 03722, South Korea., Menne T; Northern Institute for Cancer Care, Newcastle University, NE7 7DN, UK., Mariz J; Department of Onco-Hematology, Portuguese Institute of Oncology, Rua Dr Antonio Bernardino de Almeida, Porto, 4200-072, Portugal., Ilyin N; Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, p. Pesochny, 197758, Russia., Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, 331-115 Kraków, Poland., Lopez Martinez A; Department of Hematology, Hospital Arnau de Vilanova, Valencia, Comunidad Valenciana, 46015, Spain., Samoilova O; Department of Hematology, Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, 603126, Russia., Zhavrid E; N. N. Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Lesnoy, Minsk, 223040, Belarus., Yañez Ruiz E; Department of Internal Medicine, Oncology-Hematology Unit, School of Medicine, Universidad de la Frontera, Temuco, 4780000, Chile., Trneny M; Department of Medicine, Charles University, 128 08, Czech Republic., Popplewell L; Toni Stephenson Lymphoma Cancer Center and Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA 91010., Ogura M; Department of Hematology and Oncology, Kasugai Municipal Hospital, Aichi 486-8510, Japan., Kim WS; Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06355, South Korea., Lee SJ; Celltrion, Inc, Incheon, 22014, South Korea., Kim SH; Celltrion, Inc, Incheon, 22014, South Korea., Ahn KY; Celltrion, Inc, Incheon, 22014, South Korea., Buske C; Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm, University Hospital of Ulm, 89081 Ulm, Germany. Electronic address: christian.buske@uni-ulm.de.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Feb; Vol. 22 (2), pp. 89-97. Date of Electronic Publication: 2021 Aug 28.

278P Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients

Autor: Krasny, S., Polyakov, S., Zhavrid, E., Khorau, A., Baranau, Y., Kozlovskaya, S., Sergeeva, O., Zharkova, K., Sufianov, A.A., Gabai, V., Shneider, A.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S485-S485

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.

Autor: Buske C; Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany., Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland., Sancho JM; Catalan Institute of Oncology-Josep Carreras Leukaemia Research Institute - Hospital Germans Trias i Pujol, Badalona, Spain., Zhavrid E; Department of Chemotherapy, Alexandrov National Cancer Centre of Belarus, Minsk, Belarus., Kim JS; Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea., Hernández-Rivas JÁ; Department of Hematology, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain., Prokharau A; Department of Oncology, Minsk City Clinical Oncology Dispensary, Minsk, Belarus., Vasilica M; Hematology Department, Fundeni Clinical Institute, Bucharest, Romania., Nagarkar R; Curie Manavata Cancer Centre, Nashik, India., Kwak L; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Kim WS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea., Lee S; Celltrion, Inc., Incheon, South Korea; and., Kim S; Celltrion, Inc., Incheon, South Korea; and., Ahn K; Celltrion, Inc., Incheon, South Korea; and., Ogura M; Department of Hematology and Oncology, Kasugai Municipal Hospital, Kasugai, Japan.

Publikováno v: Blood advances [Blood Adv] 2021 Sep 14; Vol. 5 (17), pp. 3354-3361.

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).

Autor: Syrigos K; General Hospital of Chest Diseases of Athens 'Sotiria', Athens, Greece., Abert I; Mátrai Gyógyintézet-Bronchológia, Heves, Hungary., Andric Z; Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia., Bondarenko IN; Komunalnyi zaklad Miska bahatoprofilna klinichna likarnia #4, Dnipropetrovsk, Ukraine., Dvorkin M; Clinical Oncological Dispensary, Budget Healthcare Institution of Omsk Region, Omsk, Russian Federation., Galic K; University Clinical Hospital, Mostar, Bosnia and Herzegovina., Galiulin R; Clinical Oncological Dispensary, Omsk, Russian Federation., Kuchava V; ICO-Institute of Clinical Oncology-Hospital, Tbilisi, Georgia., Sriuranpong V; Division of Medical Oncology, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand., Trukhin D; Odeskyi oblasnyi onkolohichnyi dyspanser, Odesa, Ukraine., Zhavrid E; State Institution N.N. Alexandrov Republican Scientific, Minsk Region, Belarus., Fu D; AstraZeneca Inc, Gaithersburg, MD, USA., Kassalow LM; AstraZeneca Inc, Gaithersburg, MD, USA., Jones S; Pharmora Solutions, Dorset, UK., Bashir Z; Transcrip Partners, Reading, UK. zahid.bashir@transcrip-partners.com.; Centus Biotherapeutics, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK. zahid.bashir@transcrip-partners.com.

Publikováno v: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2021 Jul; Vol. 35 (4), pp. 417-428. Date of Electronic Publication: 2021 Jul 15.